top of page

GPCR Retreat Program

Unveiling Non-Canonical Functions for Gαq Signaling Pathways

Unveiling Non-Canonical Functions for Gαq Signaling Pathways

Date & Time

Friday, November 3rd / 11:55 AM

About Catalina Ribas


"Dr. Catalina Ribas, is currently an Associate Professor at the University Autonomous of Madrid (UAM) and she has been Academic Secretary of Molecular Biology Department for several years. The research group led by Dr. Catalina Ribas, located in the Centro de Biología Molecular “Severo Ochoa” (UAM/CSIC) and belongs also to the Health Research Institute La Princesa, has extensive experience in the field of GPCR. Dr. Catalina Ribas made a postdoctoral stay in the laboratory of Dr. SM. Lanier in the MUSC (USA). During this period and her doctoral thesis, she has deepened the regulatory mechanisms of GPCR signaling. In her postdoctoral period, she has participated in the identification and characterization of proteins that act at the level of G proteins and which are part of a multimolecular signaling complex (AGS, de “Activators of G-protein signaling). In Spain, Dr. Ribas continued working on the regulation of GPCR. The group of Dr. Ribas has characterized the existence of a new signaling pathway with a relevant role in cardiac hypertrophy led by a new Gαq interactome. Recently, Dr. Ribas' group has described a new interaction region in a cellular protein that has turned out to be very relevant in the control of the cellular process known as autophagy. These results have been published in the journal Nature Communications (12 (1):4540, 2021) with the title "Gαq controls autophagy via modulation of the mTORC1 signaling hub". Furthermore, Dr. Ribas has also described a new protective role of G protein-coupled receptor kinase 2 (GRK2), a known regulator of Gq-GPCR signaling in HNSCC tumor progression (International Journal of Cancer, 2020)."



Catalina Ribas on the web


Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec


22nd GPCR Retreat Sponsored by


 

Canada Research Chairs
U of Ottawa
Dr. GPCR
Canadian Institutes of Health Research
Bristol Myers Squibb
InversAgo Pharma
Monica Seger and Family
Duke University, Dept. Cell Biology
OHRI Neurosciences Program
University of Toronto Mississauga
Domain Therapeutics NA Inc.
Otsuka Pharmaceuticals
McGill University, Dept. Pharmacol & Exp Ther
University of Toronto, Dept. of Physiology
Hotchkiss Brain Institute,University of Calgary
OHRI
Université de Montréal, VP Office
Find Therapeutics
University of Toronto, Dept. Pharmacol & Toxicol
Deep Apple
University of Illinois at Chicago (Mark Rasenick)
uOttawa, VP Research Office
American Society of Pharmacology and Experimental Therapeutics
University of Western Ontario Schulich School of Medicine & Dentistry
Heliyon
Université de Sherbrooke, Dept. Pharmacology-Physiology
Research Institute McGill Univ. Health Centre
adMare Bioinnovations
Superluminal
Université de Montréal, Faculty of Medicine
Université de Sherbrooke, Institut de Pharmacologie
Science Signaling
Montana Molecular
IRIC
uOttawa, Dept. Cellular & Molecular Medicine
uOttawa, Dept. Biochem Microbiol Immunol
uOttawa, Behavioral & Physiology Core